GlassScriptPhysician profile
Melissa L Smith
NPI 1659366250
$2,175.44
in general payments reported to CMS, 2019-2025
32 companies · $104 in 2025
The $104 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $909 · 2020: $181 · 2021: $89.30 · 2022: $297 · 2023: $260 · 2024: $336 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $345.72 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $194.94 | 2019-2025 | |
| Abbvie INC. | $180.80 | 2022-2024 | Vraylar |
| Novo Nordisk INC | $146.34 | 2019-2023 | Wegovy |
| Janssen Pharmaceuticals, INC | $145.20 | 2019-2023 | Ponvory, Spravato |
| Smith+Nephew, INC. | $115.75 | 2019 | |
| Lilly USA, LLC | $115.67 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.28 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $108.26 | 2020 | |
| Organogenesis INC. | $96.99 | 2019-2020 | |
| Organon LLC | $61.34 | 2022-2023 | Nexplanon |
| Viiv Healthcare Company | $56.97 | 2023-2024 | Dovato |
| Glaxosmithkline, LLC. | $43.20 | 2019 | |
| Abbott Laboratories | $39.97 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Astellas Pharma US INC | $39.00 | 2019-2025 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $37.97 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.35 | 2022-2024 | Xifaxan |
| Corium, LLC | $30.62 | 2025 | Azstarys |
| Merck Sharp & Dohme LLC | $29.71 | 2019-2021 | |
| Dynavax Technologies Corporation | $23.22 | 2024 | Heplisav-B |
| Acera Surgical, INC. | $23.16 | 2023 | Restrata Wound Matrix |
| Hydrofera LLC | $22.88 | 2023 | Hydrofera Blue |
| Exeltis, USA INC. | $18.60 | 2024 | Slynd |
| Amgen INC. | $18.31 | 2019 | |
| Exact Sciences Corporation | $16.91 | 2024 | Cologuard Collection Kit |
| Shire North American Group INC | $16.85 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15.96 | 2022 | |
| Genentech USA, INC. | $15.42 | 2019 | |
| Molnlycke Health Care US, LLC | $14.25 | 2019 | |
| Amarin Pharma, INC. | $13.75 | 2019 | |
| Gilead Sciences, INC. | $11.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.